Declining HIV incidence in sub-Saharan Africa: a systematic review and meta-analysis of empiric data

3

6

Keya Joshi^{1,2}, Justin Lessler², Oluwasolape Olawore², Gideon Loevinsohn^{2,3}, Sophrena Bushey², Aaron
 A.R. Tobian^{2,4}, M. Kate Grabowski^{2,4}

- 7 1. Department of Epidemiology, Harvard TH Chan School of Public Health, Cambridge, MA, USA
- 8 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
- 9

USA

- 10 3. Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 11 4. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
- 12
- 13 Corresponding author: M. Kate Grabowski, Suite 446C Carnegie Building, 600 N. Wolfe St., Baltimore,
- 14 MD, USA 21287, mgrabow2@jhu.edu
- 15
- 16

It is made available under a CC-BY 4.0 International license .

17 ABSTRACT (249/250)

18

Background: UNAIDS models suggest HIV incidence is declining in sub-Saharan Africa; however, it is
 unclear whether modeled trends are supported by empirical evidence.

21

22 Methods: We conducted a systematic review and meta-analysis of adult HIV incidence data from sub-

23 Saharan Africa by searching Embase, Scopus, PubMed, and OVID databases and technical reports

published between January 1, 2010 and July 23, 2019. We included studies that directly measured

25 incidence from blood samples. Incidence data were abstracted according to population risk group,

26 geographic location, sex, intervention arm, and calendar period. Weighted regression models were used to

assess incidence trends across general population studies by sex. We also identified studies reporting ≥ 3

28 incidence measurements since 2010 and assessed trends within them.

29

30 Findings: 292 studies met inclusion criteria. Most studies were conducted in South Africa (n=102), Uganda (n=46), and Kenya (n=41); there were 27 countries with no published incidence data, most in 31 32 western and central Africa. Across general population studies, average annual incidence declines since 33 2010 were 0.16/1000 person-years (95% CI:0.06-0.26;p=0.004) among men and 0.16/1000 person-years (95%CI: -0.01-0.33;p=0.060) among women in eastern Africa, and 0.25/1000 person-years (95%CI:0.17-34 35 034;p<0.0001) among men and 0.42/1000 person-years (95%CI:0.23-0.62;p=0.0002) among women in 36 southern Africa. In 9/10 studies with multiple measurements, incidence declined over time. Incidence was 37 typically higher in women than men (median ratio=1.45, IQR: 1.12-1.83) with increasing sex disparity over time. 38

It is made available under a CC-BY 4.0 International license .

- 40 **Interpretation**: Empirical incidence data show the rate of new HIV infections is declining in eastern and
- 41 southern Africa. However, recent incidence data are non-existent or very limited for many countries,
- 42 particularly in western and central Africa.
- 43 **Funding:** National Institute of Allergy and Infectious Diseases
- 44
- 45

It is made available under a CC-BY 4.0 International license .

46 **INTRODUCTION**

Nearly 40 years into the HIV pandemic, sub-Saharan Africa remains the global epicenter of HIV 47 transmission, accounting for 57% of all new infections in 2019¹. Within most African countries, 48 49 transmission continues to be generalized with substantial rates of new infections outside of clearly defined risk groups, particularly in eastern and southern Africa¹. Widespread community transmission within the 50 51 region has spurred substantial investment in population-based infection control measures, including 52 biomedical and behavioral interventions. Domestic and international donors, including the Global Fund to 53 Fight AIDS, Tuberculosis, and Malaria and the United States President's Emergency Plan for AIDS 54 Relief (PEPFAR), continue to support HIV programming in sub-Saharan African with significant 55 financial and human resources investment in large-scale HIV testing, prevention, and treatment programs. 56 However, global funding for HIV programming within Africa is waning, potentially jeopardizing progress towards UNAIDS fast track goals to end the African epidemic by 2030^2 . Measuring the impact of 57 58 programmatic investments to control HIV is critical for demonstrating headway, appropriately targeting 59 future funding and other resources, and ensuring a sustained global commitment to ending the HIV 60 pandemic.

61

62 Key epidemiologic metrics of HIV control include absolute rates of HIV incidence and AIDS-related deaths and percent reductions in new infections and AIDS-related deaths among other benchmarks^{3,4}. 63 While each of these control criteria provide key insights into epidemic trajectories, HIV incidence is 64 65 arguably the most important of these metrics because it is less impacted by fluctuations in non-HIV mortality and more comparable across different population and geographic settings⁴. However, directly 66 67 observed HIV incidence measurements are difficult to obtain partly due to delays in testing following 68 infection, limited availability of testing to detect early HIV infections, and difficulty enumerating and 69 following populations at risk. Thus, data on HIV incidence trends in sub-Saharan Africa predominantly

It is made available under a CC-BY 4.0 International license .

70	come from UNAIDS mathematical models which use demographic, HIV prevalence, and programmatic
71	data ⁵⁻⁸ . Based on these models, UNAIDS reports HIV incidence is steadily declining across sub-Saharan
72	Africa. However, there are limited direct empirical data supporting these modeled downward trends. The
73	last comprehensive systematic review of the empiric HIV incidence literature from sub-Saharan Africa
74	was published in 2009 ⁹ . This prior review, including only 57 studies, found that HIV incidence data from
75	western and central Africa were rare and that estimates varied substantially within country and across
76	population risk groups: no trend data were analyzed.
77	
78	Here, we provide an update on empirical HIV incidence data published over the last decade. Our
79	systematic review and meta-analysis includes all studies reporting directly observed HIV incidence
80	measurements obtained using serologic assays either through prospective or cross-sectional assessments.
81	Data were stratified by gender and risk group where possible. Regional variation in incidence data are
82	reported along with trends over time across and within studies, by sex, and across various population risk
83	groups, including men who have sex with men (MSM) and sex workers.
84	
85	
86	
87	
88 89	
90	
91	
92	
93	
94	
95	
96	

It is made available under a CC-BY 4.0 International license .

97 **METHODS**

98 Screening and Extraction Protocol

99 We performed a systematic literature review and meta-analysis to identify studies on HIV incidence from

sub-Saharan Africa published between January 1, 2010 and July 23, 2019. We searched PubMed,

101 Embase, Scopus, and OVID global health databases for peer-reviewed articles reporting directly observed

102 (i.e. empirical) estimates of HIV incidence measured through either prospective repeat testing or cross-

sectional HIV incidence testing of blood samples. We used the following search terms "HIV",

104 "incidence", and "Africa" as medical subject heading (MESH) terms. Additional clinical synonyms and

alternative spellings were also included in the search (see supplemental methods for full search criteria).

106 Technical reports measuring population-level HIV incidence, but not published in peer-reviewed journals,

107 such as the population-based HIV impact assessment (PHIA) surveys, were also included.

108

109 Our analysis included peer-reviewed studies and technical reports including national or subnational

110 empiric estimates of HIV incidence from sub-Saharan Africa. We excluded studies of HIV not in humans,

studies reporting incidence estimates for children < 15 years of age only, studies not in English,

112 perspectives, opinions, commentaries, case-control studies, studies measuring impact of post-exposure

113 prophylaxis among health care workers (HCW), cross-sectional incidence studies only including HIV-

114 positive persons, and incidence estimates based on mathematical models. We further excluded studies

115 with incidence estimates based on less than 50 total participants or less than 50 person-years at risk

116

After removal of duplicates, all studies identified through the database search were uploaded to the
Covidence systematic review management software and then screened by two independent reviewers (KJ,
SB, GL, OO)¹⁰. Studies first went through a title and abstract review. Those deemed eligible went through
further full text review. As defined in the protocol, any disagreement at each stage was resolved through
consensus.

It is made available under a CC-BY 4.0 International license .

122	We extracted standardized data from each study including study design, study cohort, geographic location
123	(ISO1-ISO3, where applicable), dates of data collection (i.e. the study period), incidence rate (including
124	95% confidence intervals [95%CI] and standard errors [SE]), cumulative incidence (including 95% CIs
125	and SEs), person-years (pys) at risk, number of HIV seroconversions, number of individuals in the study
126	overall and by sex and age where applicable, total numbers of HIV-negative and positive participants at
127	baseline, and a description of the intervention if the study was a randomized clinical trial (RCT). Data
128	from multi-center RCTs were disaggregated by site if possible. Incidence rates were further disaggregated
129	by sex, age group/range, population risk group, and intervention arm when available. Population risk
130	groups included sex workers (SW), men who have sex with men (MSM), transgender women (TGW),
131	pregnant women (PW), serodiscordant couples (SDC), Lake Victoria fisherfolk (FF), other high risk
132	populations (e.g., women with multiple sexual partners; bar workers), and general populations (i.e.,
133	geographically defined populations with no defining characteristics beyond location of residency). For
134	studies measuring cross sectional incidence through either BED TM capture enzyme immunoassay (BED-
135	CEIA) or Limiting Antigen avidity (LAg-Avidity) enzyme immunoassay, we also recorded information
136	on the window period, false recency rate and optical density (OD) reported.
137	
138	For incidence rates, all estimates were converted to number of seroconversions per 100 pys at risk. We
139	did not assess study quality or perform a risk of bias assessment for three reasons: (1) rates of HIV
140	incidence were expected to vary across geography and between risk groups, (2) our primary objective was
141	to summarize incidence data as opposed to assessing the causal impact of any particular intervention or
142	exposure, and (3) there was substantial heterogeneity in the methods used to obtain incidence estimates.
143 144	Statistical Analysis
145	Studies were grouped into geographic regions as defined by the UN Statistics Division ¹¹ . However,
146	Malawi, Mozambique, Zambia and Zimbabwe were categorized as part of the southern region, and Sudan

It is made available under a CC-BY 4.0 International license .

147 as part of the eastern region, due to the similarity of their epidemic, most notably subtype distribution,148 with other countries in those respective regions.

149

150 We summarized HIV incidence trends across general population studies over calendar time for eastern 151 and southern Africa by using weighted loess regression for studies in which the calendar midpoint of the data collection period occurred on or after October 8, 2006 (i.e., the $>25^{\text{th}}$ percentile of the distribution of 152 153 data collection calendar midpoints). Weights corresponded to the study size (N) of the population. In 154 order to estimate the rate of change in incidence since 2010, we fit weighted linear regression models 155 weighted by study size for all studies in which the calendar midpoint of the data collection period was in 156 2010 or later. For countries where study size was not reported for a specific time-point, the most recent 157 study size reported either at follow-up or baseline was used. All trend analyzes were stratified by sex. We 158 excluded studies that only reported incidence estimates for men and women combined, age-specific 159 incidence estimates for age bins less than 26 years, and studies that reported incidence estimates for non-160 general population subgroups. The 26 year cutoff was chosen because it was the smallest age bin including more than two thirds (>70%) of the adult population most at risk for HIV, typically defined as 161 162 15-49 years old. For studies where CIs were not reported, we derived exact confidence intervals based on 163 a Poisson distribution. Studies that did not report an upper or lower age limit were included (e.g., studies 164 that reported a minimum enrollment of 15 years but no max age enrollment), but these studies were 165 excluded in sensitivity analyses. Point estimates were plotted at the midpoint of the data collection period 166 (e.g. if a study was conducted from January 1, 2010 to December 31, 2010, the study midpoint would be 167 July 2, 2010) with bars indicating the entire length of the collection period (e.g. January 1, 2010 and 168 December 31, 2010). Trends in HIV incidence were not examined for western or central Africa or for 169 other population risk groups given limited availability of incidence data.

170

We further summarized recent incidence trends over the last decade within study cohorts over time usinglinear regression models. This analysis was limited to studies that reported incidence estimates for at least

It is made available under a CC-BY 4.0 International license .

173	three unique calendar periods since January 1, 2010. For studies that reported age-stratified estimates, we
174	used incidence metrics for the widest age bin reported, but did not restrict based on age-bin size.
175	
176	We constructed forest plots to summarize HIV incidence rates and 95% confidence intervals by region
177	and risk group. For studies where incidence estimates were reported for multiple time periods, we only
178	included the most recent estimate. Similarly, if multiple studies reported estimates from the same cohort,
179	we used the most recent estimate available. For RCTs, we included the estimate from the control arm
180	only. For studies reporting estimates disaggregated by type of hormonal contraceptive use, we included
181	the incidence estimate among women using either no contraceptive, or non-hormonal contraceptives. For
182	studies reporting both national and sub-national incidence data, estimates at the national level only were
183	included. For general population studies, we only reported incidence estimates for age bins spanning 26
184	years or greater.
185	
186	All analyses were conducted in R (version 3.6.2) and Stata (version 14).
187	
188	Role of the funding source
189	The funders of the study had no role in study design, data collection, data analysis, data interpretation, or
190	writing of the report. The corresponding author had full access to all the data in the study and had final

191 responsibility for the decision to submit the application.

It is made available under a CC-BY 4.0 International license .

193 **RESULTS**

194

There were 34,781 records retrieved through the database searches and an additional 11 technical reports 195 196 identified and included. After duplicates were removed, 18,295 records remained. 17,890 records were 197 excluded after title and abstract screening, with 405 records remaining for full text review. Of these, 113 studies were excluded due to not meeting pre-specified inclusion criteria. There were 292 studies that 198 reported some form of HIV incidence data (e.g., cumulative incidence, number of seroconversions, 199 200 incidence rate), and 237 for which at least one incidence rate estimate was reported or could be derived 201 (n = 229 reported and n = 8 derived, Figure 1; Supplemental Table 1).202 203 The 292 studies reported incidence data from 23 sub-Saharan countries (Figure 2A). Most studies were 204 conducted in South Africa (n = 102), Uganda (n = 46), Kenva (n = 41), Zimbabwe (n = 21) and Tanzania 205 (n = 14). Of note, there were 43 incidence estimates reported from multi-country studies (e.g. studies reporting combined estimates from two or more countries). While the number of studies published per 206 207 country correlated with total case burden (Figure 2B), there were 26 countries in sub-Saharan Africa with 208 no published incidence data. The majority of these countries were in western and central Africa, including 209 Angola, Cape Verde, Central African Republic, Chad, Congo, Democratic Republic of Congo, Diibouti, 210 Equatorial Guinea, Eritrea, Gabon, Gambia, Guinea, Liberia, Madagascar, Mauritius, Sierra Leone,

211 Senegal, South Sudan, and Togo.

212

Figure 2C shows the number of studies reporting incidence data versus the prevalence of infection at the country level using 2018 national prevalence estimates from USAID¹². Of the five countries with the highest HIV prevalence, there were only two with more than 10 studies published since 2010 (South Africa with 102 estimates and an HIV prevalence of 20.4%, Zimbabwe with 21 estimates and a prevalence of 12.7%). The remaining three countries, eSwatini, Lesotho, and Botswana had prevalences

It is made available under a CC-BY 4.0 International license .

of 27.3%, 23.6% and 20.3%, but only had 4, 3, and 5, incidence studies published, respectively (Figure
3A).

220

221	Publication of incidence data fluctuated little over calendar time (Figure 3A). Most incidence estimates
222	were derived from prospective observational cohort studies (n=163), followed by secondary analyses of
223	RCTs ($n = 46$), cross-sectional incidence studies ($n = 42$), primary analyses of RCTs ($n=34$), serial cross-
224	sectional studies ($n = 7$), retrospective cohort studies ($n = 6$), and nested case control studies ($n = 1$). Of
225	note, there were 7 studies reporting incidence data from two design classifications. Figure 3B shows
226	studies disaggregated by population risk group. 152 estimates were drawn from GP studies, 41 from SDC,
227	33 from PW, 31 from sex workers SW, 11 from MSM, and 10 from FF communities in eastern Africa.
228	
229	Next we summarized HIV incidence trends over calendar time for GP studies by sex and geographic
230	region (Figure 4). A total of 50 studies contributed 146 estimates (n=83 for women; n=63 for men) to the
231	analysis. Across both southern and eastern Africa, we observed declines in HIV incidence since 2010 in
232	both sexes. In eastern Africa, annual incidence declined by 0.16/1000 pys (95%CI: 0.06-0.26; p=0.004)
233	among men and by 0.16/1000 pys (95%CI: -0.01-0.33; p=0.060) among women. HIV incidence fell more
234	rapidly in southern Africa, declining by 0.25/1000 pys (95%CI: 0.17-0.34; p<0.0001) annually among
235	men and by 0.42/1000 pys (95%CI: 0.23-0.62; p=0.0002) annually among women. In sensitivity analyses,
236	we excluded studies that did not report either an upper or lower age range (n=15) and observed similar
237	trends (Supplemental Figure 1).
238	
239	We also examined HIV incidence trends within studies that had more than three incidence rate
240	measurements in unique calendar periods since January 1, 2010 (Figure 5). Of the 292 studies, only 38
241	(13%) studies reported incidence rate estimates for more than one unique calendar period (Supplemental

Figure 2), and of these studies only 10 had 3 or more measurements since 2010. Within nine of these

It is made available under a CC-BY 4.0 International license .

studies, a decline in HIV incidence was observed over calendar time. The single outlier study showed
rising incidence among pregnant women in South Africa¹³.

245

246 Figures 6 summarizes the most recent HIV incidence estimates since 2010 for GP studies in southern 247 Africa. National estimates ranged from 0.37 per 100 pys in Malawi (2015-2016) to 2.4 per 100 pys in 248 eSwatini (2010-2011). However, by 2016-2017, HIV incidence declined to 1.13 per 100 pys in eSwatini. 249 There was substantial variation across national and sub-national incidence estimates in South Africa with 250 rates ranging 0.69 at the national level to 3.28 pys sub-nationally. Of the 4 measurements exceeding 2 per 251 100 pys, 3 were in South Africa and 1 in eSwatini. Overall, South Africa reported the highest rates of HIV 252 incidence in the general population, and these estimates were predominately concentrated in KwaZulu-253 Natal, a coastal province in the southeast. 254 255 Supplemental Figure 3 shows the most recent HIV incidence estimates since 2010 for general population

studies in eastern Africa. Estimates ranged from 0.06 per 100 pys (95%CI: 0-0.12) in Ethiopia to 3.4 per
100 pys (no confidence interval reported) in Sudan. National studies were conducted in Ethiopia, Kenya,
Rwanda, Uganda, and Tanzania and all HIV incidence estimates were below 1 per 100 pys. There were
only two general population studies in west Africa since 2010, including the Cameroon PHIA in 2017-18
which reported an HIV incidence rate of 0.27 (95%CI: 0.14-0.41) per 100 pys¹⁴, and another study in
blood donors in Cote d'Ivoire (0.07 per 100 pys; 95%CI: 0.06-0.08)¹⁵.

262

We also collated recent HIV incidence estimates for key populations, including SW, MSM, and FF (Supplementary Figures 4-6). Overall, there were few incidence estimates available for these groups since 2010; however, incidence rates in these populations were typically much higher than that observed in GP studies. All estimates for SWs (n=7) were derived from cohort studies and ranged from 0.6 to 3.4 per 100 pys (Supplemental Figure 4). Incidence estimates among MSM cohorts (n=5) were highly variable ranging from 1.03 per 100 pys (95% CI: 0.03-5.79) in Kenya to 15.4 per 100 pys (95% CI: 12.3-19) in

It is made available under a CC-BY 4.0 International license .

Nigeria (Supplemental Figure 5). Among FF populations, HIV incidence ranged from 1.59 to 6.04 per
100 pys (Supplemental Figure 6).

271

- 272 Lastly, we directly compared HIV incidence estimates between men and women within GP studies
- (Figure 7). Of the 237 studies with incidence rates reported, 108 (46%) reported incidence estimates for
- women only and 18 (8%) for men only. There were an additional 23 (10%) studies that reported
- combined estimates for men and women only, and 88 (37%) studies reported sex stratified results
- 276 including both sexes. Among 44 GP studies reporting 96 sex stratified incidence estimates for age bins
- ≥ 26 years, female HIV incidence was higher in 78 (81%) instances and the median female to male HIV
- incidence ratio was 1.45 (IQR: 1.12-1.83) overall (Figure 7A). Temporal assessment of the female to
- 279 male incidence rate ratio showed evidence for growing disparity by sex over calendar time, increasing by
- 280 2.4% per year on average (95CI:1.14-3.74%, p=0.0003; Figure 7B).

281

It is made available under a CC-BY 4.0 International license .

283 **DISCUSSION**

284	Monitoring HIV incidence trends is critical for assessing progress and targeting resources. Our analysis of
285	directly observed HIV incidence data demonstrates that the rate of new infections is rapidly declining in
286	eastern and southern Africa among both men and women. These findings are consistent with UNAIDS
287	incidence models which have also shown reductions in new cases continent-wide over the last decade ^{1,6} .
288	However, there are notable gaps in the availability of empiric HIV incidence data, particularly for western
289	and central Africa and among key populations, including MSM among whom HIV incidence was highest.
290	HIV incidence remains higher among women, despite overall reductions in acquisition risk in both sexes,
291	and the incidence gap between sexes appears to be growing with time.
292	
293	The last comprehensive systematic review of the empiric HIV incidence literature in sub-Saharan Africa
294	was published in 2009 and included 57 studies conducted in 14 sub-Saharan African countries ⁹ . In this
295	this systematic review of incidence data published between 2010 and 2019, incidence estimates were
296	available for 23 sub- countries; however, data were non-existent or sparse in many countries. Of the 292
297	studies included in this study, only 20 (7%) were conducted in western and central Africa, despite this
298	region accounting for an estimated 25% of all incidence cases in sub-Saharan Africa in 2019 ¹ . Critically,
299	16 countries in western and central Africa reported no incidence data at all, illuminating critical
300	geographic gaps in surveillance and interventional research efforts. While the number of studies
301	conducted per country tended to trend with higher HIV case burden and prevalence, there were several
302	countries with either moderately high case burden or prevalence reporting no or very limited data,
303	including the Democratic Republic of Congo and Equatorial Guinea. Similar geographic disparities in
304	incidence data have been reported earlier ⁹ .

It is made available under a CC-BY 4.0 International license .

306	We observed steadily declining HIV incidence rates across general population studies in eastern and
307	southern Africa since 2010. While HIV incidence was consistently higher among women than men, there
308	were significant reductions in incidence rates in both sexes. Notably, there was a 50% reduction in HIV
309	incidence in eSwatini between 2010 and 2017, the largest national decline reported. These broad
310	reductions in HIV incidence are likely the partial result of massive global efforts to rollout and scale-up
311	HIV prevention and treatment interventions, including antiretroviral therapy (ART) and voluntary
312	medical male circumcision (VMMC). Indeed, several population-based cohorts and RCTs have reported
313	on the link between ART and VMMC and declines in population-level incidence ^{16–22} .
314	

315 Overall, only 16% of studies reported HIV incidence measurements at multiple time points within the 316 same study population. However, nearly half of these studies ended prior to 2010 before the scale-up of major prevention and treatment interventions, resulting in unfortunate lost opportunity to evaluate their 317 318 impact. Of the ten studies that obtained more than two incidence measurements after 2010, all but one 319 showed evidence of declining HIV incidence, consistent with our analyses of incidence across general population studies. Of note, two of these nine studies were conducted in high risk key populations, one 320 among Lake Victoria fisherfolk and the other among sex workers^{16,23}, suggesting incidence reductions 321 322 may not be exclusive to general population cohorts.

323

At the sub-national level we found substantial variation in HIV incidences rates. These findings are consistent with recent a study that reported marked small-scale spatial heterogeneities in disease burden across the continent²⁴. While some variation in rates is likely due to temporal heterogeneities, there were countries that reported estimates over similar calendar periods (e.g., South Africa) with substantial variation in incidence. Prior studies in South Africa have identified high risk corridors of transmission with elevated HIV incidence rates compared to the surrounding population²⁵. Furthermore, these areas

It is made available under a CC-BY 4.0 International license .

tended to correlate with higher prevalence, suggesting that current maps of HIV prevalence, potentially in
combination with uptake of HIV prevention and treatment data, could be used to strategically implement
HIV programs and target interventions, such as pre-exposure prophylaxis (i.e., PrEP), to high risk
populations.

334

In general population studies, HIV incidence was nearly always higher among women, a finding 335 336 consistent with a recent systematic review of incidence among African adolescents and young adults 15-24 years old^{26} . Notably, nearly half of all incidence studies were conducted among women, while just 337 338 under 10% were conducted among men only. A better understanding of incidence and associated risk 339 factors for transmission among men might potentially result in lower female transmission given the large preponderance of heterosexual HIV transmission in Africa¹. Studies throughout Africa show lower uptake 340 of HIV prevention and treatment interventions among men, but also lower participation rates in many 341 HIV incidence studies²⁷. We also found the ratio of female to male HIV incidence increased over calendar 342 343 time. It is unclear what is driving this growing HIV disparity between men and women; however, lower 344 male susceptibility due to increasing VMMC coverage and higher female ART uptake may partially 345 explain this observation.

346

In line with prior systematic reviews^{28,29}, we found substantially higher estimates of HIV incidence among key populations, including Lake Victoria fisherfolk, MSM, and sex workers, as compared to general population cohorts. However, there were relatively few studies in these populations overall, and among them there was substantial variation in HIV incidence. MSM had the highest HIV incidence rates of any sub-group, consistent with prior studies showing extremely high HIV prevalence among African MSM²⁸.

It is made available under a CC-BY 4.0 International license .

354 There are limitations to this study. First, the methods used to obtain HIV incidence estimates across 355 studies, including study design, testing algorithms, and definitions of incidence were highly variable. 356 Second, upper and lower age eligibility criteria were often unreported. In the case of general population 357 studies that did not report an upper or lower age bound, we imputed the range to be 15-65 years. In a 358 sensitivity analysis assessing incidence trends over calendar time, we excluded these studies and found no 359 qualitative differences in our inferences. Third, there were many countries and geographic locations for 360 which there were no incidence data available. It is unclear whether the data presented here are representative of empirical trends in unobserved locations, most notably western and central Africa. 361 362 Reassuringly, our results are consistent with UNAIDS regional models of incidence trends also showing declines in new cases over the same time frame¹. Additionally, our analysis of incidence trends were only 363 364 done among general population cohorts and thus may not reflect changes among key populations. Fourth, 365 published data may not be fully representative of all incidence data, particularly studies with higher incidence rates may be more likely to be published than those with low or zero incidence. Lastly, the 366 367 results of this study may have been impacted by our own review methodologies, including the search strategy and our inclusion and exclusion criteria. Critically, we excluded studies that were not in English, 368 369 which may explain some of the data gaps observed in western and central Africa.

370

371 In conclusion, our findings provide empirical evidence that HIV incidence in eastern and southern Africa 372 has declined over the last decade. The widespread scale-up and uptake of HIV treatment and prevention interventions has been linked to incidence declines within individual studies previously¹⁶⁻²², and are likely 373 contributing to the broad scale incidence reductions observed here. Sustained commitment to these 374 375 programs and new investment in innovative technologies and approaches may ultimately help achieve HIV elimination goals in sub-Saharan Africa. However, future successes remain in the balance as global 376 377 funding for HIV programs in low and middle-income countries dwindles². The COVID-19 pandemic 378 presents further challenges as critical resources are diverted and mobility restrictions impact uptake of

It is made available under a CC-BY 4.0 International license .

- interventions, in particular, HIV testing and timely initiation of ART^{30,31}. Ongoing surveillance, including
- addressing geographic and population disparities in HIV incidence data, will be critical to maintaining
- and building upon past success in the coming decade.

It is made available under a CC-BY 4.0 International license .

383 **References**

- 384
- 1 2020 Global AIDS Update
 — Seizing the moment
 — Tackling entrenched inequalities to end
 epidemics | UNAIDS. https://www.unaids.org/en/resources/documents/2020/global-aids-report
 (accessed Oct 7, 2020).
- Kates J, Wexler A. Donor Government Funding for HIV in Low- and Middle-Income Countries in
 2019.
- 390 3 Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and
 benchmarks for a transition in the HIV epidemic. *PLoS Med* 2018; **15**: e1002678.
- Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE. Defining control of HIV epidemics.
 Lancet HIV 2018; 5: e667–e670.
- GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of
 HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the
 Global Burden of Diseases, Injuries, and Risk Factors Study 2017. *Lancet HIV* 2019; 6: e831–e859.
- Mahy M, Marsh K, Sabin K, Wanyeki I, Daher J, Ghys PD. HIV estimates through 2018: data for
 decision making. *AIDS* 2019; published online July 22. DOI:10.1097/QAD.00000000002321.
- Eaton JW, Brown T, Puckett R, *et al.* The Estimation and Projection Package Age-Sex Model and the
 r-hybrid model: new tools for estimating HIV incidence trends in sub-Saharan Africa. *AIDS* 2019; 33
 Suppl 3: S235–S244.
- 8 Stover J, Brown T, Puckett R, Peerapatanapokin W. Updates to the Spectrum/Estimations and
 Projections Package model for estimating trends and current values for key HIV indicators. *AIDS*2017; 31 Suppl 1: S5–S11.
- Braunstein SL, van de Wijgert JHHM, Nash D. HIV incidence in sub-Saharan Africa: a review of
 available data with implications for surveillance and prevention planning. *AIDS Rev* 2009; 11: 140–
 156.
- 408 10 Covidence Better systematic review management. https://www.covidence.org/ (accessed Oct 12, 2020).
- 410 11 UNSD Methodology. https://unstats.un.org/unsd/methodology/m49/ (accessed Oct 12, 2020).
- 411 12 UNAIDS Data 2019. 2019; published online July 16.
- https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf (accessed Oct 12, 2020)
- 13 Chetty T, Vandormael A, Thorne C, Coutsoudis A. Incident HIV during pregnancy and early
 postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa. *BMC Pregnancy Childbirth* 2017; **17**: 248.
- 417 14 President's Emergency Plan for AIDS Relief. Cameroon Population based HIV Impact Assessment 2017. 2020.
- 419 15 Seri B, Minga A, Gabillard D, *et al.* Twenty-Year Evolution of Hepatitis B Virus and Human
 420 Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood Donors in Côte d'Ivoire. *Open*421 *Forum Infect Dis* 2018; **5**: ofy060.

It is made available under a CC-BY 4.0 International license .

- 422 16 Kagaayi J, Chang LW, Ssempijja V, *et al.* Impact of combination HIV interventions on HIV incidence
 423 in hyperendemic fishing communities in Uganda: a prospective cohort. *Lancet HIV.* 6: e6680-e687
- 424 17 Grabowski MK, Serwadda DM, Gray RH, *et al.* HIV prevention efforts and incidence of HIV in
 425 uganda. *N Engl J Med* 2017; **377**: 2154–2166.
- 18 Borgdorff MW, Kwaro D, Obor D, *et al.* HIV incidence in western Kenya during scale-up of
 antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis. *Lancet HIV* 2018; 5: e241–e249.
- Hayes RJ, Donnell D, Floyd S, *et al.* Effect of Universal Testing and Treatment on HIV Incidence HPTN 071 (PopART). *N Engl J Med* 2019; **381**: 207–218.
- 20 Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with
 decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. *Science* 2013; **339**: 966–971.
- 433 21 Havlir DV, Balzer LB, Charlebois ED, *et al.* HIV Testing and Treatment with the Use of a
 434 Community Health Approach in Rural Africa. *N Engl J Med* 2019; **381**: 219–229.
- 435 22 Makhema J, Wirth KE, Pretorius Holme M, *et al.* Universal Testing, Expanded Treatment, and
 436 Incidence of HIV Infection in Botswana. *N Engl J Med* 2019; **381**: 230–242.
- 437 23 McClelland RS, Richardson BA, Cherutich P, *et al.* A 15-year study of the impact of community
 438 antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. *AIDS* 2015; 29:
 439 2279–2286.
- 24 Dwyer-Lindgren L, Cork MA, Sligar A, *et al.* Mapping HIV prevalence in sub-Saharan Africa
 between 2000 and 2017. *Nature* 2019; published online May 15. DOI:10.1038/s41586-019-1200-9.
- Tanser F, Bärnighausen T, Dobra A, Sartorius B. Identifying "corridors of HIV transmission" in a
 severely affected rural South African population: a case for a shift toward targeted prevention
 strategies. *Int J Epidemiol* 2018; **47**: 537–549.
- 26 Birdthistle I, Tanton C, Tomita A, *et al.* Recent levels and trends in HIV incidence rates among
 adolescent girls and young women in ten high-prevalence African countries: a systematic review and
 meta-analysis. *Lancet Glob Health* 2019; 7: e1521–e1540.
- 448 27 Adeyeye AO, Stirratt MJ, Burns DN. Engaging men in HIV treatment and prevention. *Lancet* 2018;
 449 392: 2334–2335.
- 28 Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex
 with men in low- and middle-income countries 2000-2006: a systematic review. *PLoS Med* 2007; 4:
 e339.
- 453 29 Baral S, Beyrer C, Muessig K, *et al.* Burden of HIV among female sex workers in low-income and
 454 middle-income countries: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; 12: 538–
 455 549.
- 456 30 Abdool Karim Q, Abdool Karim SS. COVID-19 affects HIV and tuberculosis care. *Science* 2020;
 457 369: 366–368.
- 458 31 Global Fund Survey: Majority of HIV, TB and Malaria Programs Face Disruptions as a Result of
 459 COVID-19 COVID-19 The Global Fund to Fight AIDS, Tuberculosis and Malaria.

It is made available under a CC-BY 4.0 International license .

- 460 https://www.theglobalfund.org/en/covid-19/news/2020-06-17-global-fund-survey-majority-of-hiv-tb-
- 461 and-malaria-programs-face-disruptions-as-a-result-of-covid-19/ (accessed Oct 17, 2020).

462

It is made available under a CC-BY 4.0 International license .

Declaration of interests.


- 466 We declare no competing interests.

469 Acknowledgements

- 470 This work was supported by the National Institute of Allergy and Infectious Diseases (K01AI125086 to
- 471 M.K.G. and R01AI120938 and R01AI128779 to A.A.R.T).
- 473 We thank Dr. Jeff Eaton if his thoughtful comments and advice on this manuscript.

It is made available under a CC-BY 4.0 International license .






485 486

Figure 1: Flow of papers from literature search to full-text review. 34,781 papers published between
2010-2019 were identified through PubMed, Embase, Scopus, and OVID global health and 11 additional
papers were identified through alternative sources including PHIA surveys. 16,497 duplicates were
removed using Covidence. Of the 18,295 studies screened, 292 papers met eligibility criteria and were

491 included in the analysis.


It is made available under a CC-BY 4.0 International license .




- 497
- 498
- 499

500 Figure 2: Number of studies reporting empirical HIV incidence data published between 2010-2019 by location, HIV burden, and study period. (A). Number of studies by country in sub-Saharan Africa. 501 Studies only reporting incidence data across countries (e.g. South Africa and Zambia combined) were not 502 503 included. (B) Number of studies by number of people living with HIV. Number of people living with HIV taken as the mean estimated number of adults (15+) living with HIV in 2018 from UNAIDS. (C) Number 504 of studies by HIV prevalence and region. Prevalence taken as the 2018 adult (15-49) prevalence estimate 505 506 from UNAIDS. (D) Distribution of calendar midpoints for HIV incidence rate estimates. The median and 507 interquartile range of calendar midpoints are shown in red.

It is made available under a CC-BY 4.0 International license .









512 Number of studies published by calendar year broken down by study type (B) Number of studies

513 published by risk group broken down by study type. FF=fisherfolk, GP=general population; HR=high risk

(e.g., women who report multiple partners); MSM=men who have sex with men; MSRGs=multiple risk

- 515 groups (e.g., SW and MSM); PW=pregnant women; SDC=serodiscordant couples; SW=sex workers;
- 516 TGW= transgender women
- 517
- 518





It is made available under a CC-BY 4.0 International license

It is made available under a CC-BY 4.0 International license .




Figure 5: HIV incidence trends from 10 studies with three or more incidence rate measurements after 2010. Data is shown overall and disaggregated by sex where possible. The legend shows the first author, sex (M=male; F=female), and risk group (GP=General population; PW=pregnant women; FF=fisherfolk; SW=sex worker).




Figure 6. Forest plot of HIV incidence estimates after 2010 for general population studies in southern Africa. Only the most recent HIV incidence estimate for a cohort/study population are shown. Incidence rates are reported as the number of new cases per 100 person-years and the error bars represent 95% CI. Study references are reported in supplemental Table 1. CT=clinical trial; CSI=cross-sectional incidence study; PC=prospective cohort

It is made available under a CC-BY 4.0 International license




Figure 7. HIV incidence rates among men and women in general population studies. (A) Plot of male vs. female HIV incidence per 100 person-years. Dashed red line is the identify line; points above the line represent higher female HIV incidence while points below the line represent higher male HIV incidence. (B) Scatterplot of the log female-male HIV incidence ratio over calendar time with fitted line (solid black line) estimated using linear regression.

It is made available under a CC-BY 4.0 International license